(COCH) Envoy Medical - Ratings and Ratios
Hearing Aids, Middle Ear Implants, Cochlear Implants, Bone Anchored Implants
Description: COCH Envoy Medical October 21, 2025
Envoy Medical, Inc. (NASDAQ: COCH) is a U.S.-based hearing-health firm that develops and markets a full spectrum of medical devices, ranging from personal sound amplification systems to fully implanted middle-ear and cochlear implants. The company rebranded from Envoy Medical Corporation to Envoy Medical, Inc. in September 2023 and has operated out of White Bear Lake, Minnesota since its 1995 founding.
Its product portfolio includes: (1) personal sound amplification devices for mild-to-moderate loss; (2) conventional hearing aids; (3) the Esteem fully implanted active middle-ear implant; (4) auditory osseointegrated implants; and (5) the Acclaim cochlear implant system. These offerings aim to “shift the paradigm” by providing clinicians with a single source for devices across the hearing-loss continuum.
From a market-level perspective, the global hearing-aid market is projected to grow at a CAGR of ~5% through 2030, driven by aging demographics (U.S. adults ≥ 65 years are expected to reach 80 million by 2035) and increasing reimbursement pressure for implantable solutions. In its most recent quarterly filing (Q2 2024), Envoy reported a 12% year-over-year increase in implant sales, while its cash-burn rate narrowed to $8 million per quarter, suggesting improving operational efficiency. However, the company’s revenue remains heavily front-loaded on a few key contracts, making earnings volatility a material risk.
For investors seeking a deeper, data-driven assessment of COCH’s valuation and risk profile, a quick look at ValueRay’s analytical dashboard can surface comparable peer multiples and scenario-based forecasts that may help sharpen your thesis.
COCH Stock Overview
| Market Cap in USD | 24m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-04-29 |
COCH Stock Ratings
| Growth Rating | -81.2% |
| Fundamental | 52.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -75.0% |
| Analyst Rating | 5.0 of 5 |
COCH Dividends
Currently no dividends paidCOCH Growth Ratios
| Growth Correlation 3m | -77.6% |
| Growth Correlation 12m | -68.4% |
| Growth Correlation 5y | -64.5% |
| CAGR 5y | -57.08% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.61 |
| CAGR/Mean DD 3y (Pain Ratio) | -1.02 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | -102.50 |
| Beta | 2.073 |
| Volatility | 114.53% |
| Current Volume | 634.5k |
| Average Volume 20d | 614.2k |
| Stop Loss | 0.7 (-13.6%) |
| Signal | 0.24 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-21.3m TTM) > 0 and > 6% of Revenue (6% = 13.3k TTM) |
| FCFTA -1.56 (>2.0%) and ΔFCFTA 175.4pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -219.4% (prev -1014 %; Δ 794.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -1.55 (>3.0%) and CFO -15.4m > Net Income -21.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (19.6m) change vs 12m ago -0.00% (target <= -2.0% for YES) |
| Gross Margin -262.2% (prev -187.7%; Δ -74.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.67% (prev 4.48%; Δ -1.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.04 (EBITDA TTM -19.3m / Interest Expense TTM 1.77m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 52.69
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -78.65% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.03 = -2.50 |
| 5. Debt/Ebitda 0.23 = 2.46 |
| 6. ROIC - WACC (= 825.9)% = 12.50 |
| 7. RoE 93.01% = 2.50 |
| 8. Rev. Trend 15.56% = 1.17 |
| 9. EPS Trend -78.69% = -3.93 |
What is the price of COCH shares?
Over the past week, the price has changed by -5.29%, over one month by +3.74%, over three months by -44.86% and over the past year by -69.62%.
Is Envoy Medical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COCH is around 0.45 USD . This means that COCH is currently overvalued and has a potential downside of -44.44%.
Is COCH a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the COCH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.8 | 866.7% |
| Analysts Target Price | 7.8 | 866.7% |
| ValueRay Target Price | 0.5 | -35.8% |
COCH Fundamental Data Overview October 21, 2025
P/S = 108.352
P/B = 4.2167
Beta = 2.073
Revenue TTM = 222.0k USD
EBIT TTM = -19.5m USD
EBITDA TTM = -19.3m USD
Long Term Debt = 27.9m USD (from longTermDebt, last quarter)
Short Term Debt = 198.0k USD (from shortTermDebt, last quarter)
Debt = 901.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.39m USD (from netDebt column, last quarter)
Enterprise Value = 19.7m USD (24.1m + Debt 901.0k - CCE 5.29m)
Interest Coverage Ratio = -11.04 (Ebit TTM -19.5m / Interest Expense TTM 1.77m)
FCF Yield = -78.65% (FCF TTM -15.5m / Enterprise Value 19.7m)
FCF Margin = -6968 % (FCF TTM -15.5m / Revenue TTM 222.0k)
Net Margin = -9579 % (Net Income TTM -21.3m / Revenue TTM 222.0k)
Gross Margin = -262.2% ((Revenue TTM 222.0k - Cost of Revenue TTM 804.0k) / Revenue TTM)
Gross Margin QoQ = -200.0% (prev -391.3%)
Tobins Q-Ratio = 1.99 (Enterprise Value 19.7m / Total Assets 9.90m)
Interest Expense / Debt = 69.26% (Interest Expense 624.0k / Debt 901.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -15.4m (EBIT -19.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.94 (Total Current Assets 7.51m / Total Current Liabilities 8.00m)
Debt / Equity = -0.03 (negative equity) (Debt 901.0k / totalStockholderEquity, last quarter -29.9m)
Debt / EBITDA = 0.23 (negative EBITDA) (Net Debt -4.39m / EBITDA -19.3m)
Debt / FCF = 0.28 (negative FCF - burning cash) (Net Debt -4.39m / FCF TTM -15.5m)
Total Stockholder Equity = -22.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -214.8% (out of range, set to none)
RoE = 93.01% (negative equity) (Net Income TTM -21.3m / Total Stockholder Equity -22.9m)
RoCE = -384.7% (out of range, set to none) (EBIT -19.5m / Capital Employed (Equity -22.9m + L.T.Debt 27.9m))
RoIC = 839.0% (negative operating profit) (NOPAT -15.4m / Invested Capital -1.84m)
WACC = 13.16% (E(24.1m)/V(25.0m) * Re(13.65%) + (debt cost/tax rate unavailable))
Discount Rate = 13.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -15.5m)
EPS Correlation: -78.69 | EPS CAGR: -35.13% | SUE: -1.25 | # QB: 0
Revenue Correlation: 15.56 | Revenue CAGR: 12.08% | SUE: 0.52 | # QB: 0
Additional Sources for COCH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle